Inhibition of protein kinase CK2 reduces Cyp24a1 expression and enhances 1,25-dihydroxyvitamin D3 antitumor activity in human prostate cancer cells

Cancer Research

Volumn 73, Issue 7, 2013, Pages 2289-2297

  Luo, Wei ^a   Yu, Wei Dong ^a   Ma, Yingyu ^a   Chernov, Mikhail ^a   Trump, Donald L ^a   Johnson, Candace S ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,5,6,7 TETRABROMOBENZIMIDAZOLE; ANTINEOPLASTIC AGENT; CALCITRIOL; CASEIN KINASE II; ENZYME INHIBITOR; LUCIFERASE; MESSENGER RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CYP24A1 GENE; DOWN REGULATION; DRUG IDENTIFICATION; DRUG POTENTIATION; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE ACTIVITY; GENE DISRUPTION; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR LIBRARY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CASEIN KINASE II; CELL PROLIFERATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MALE; MICE; MICE, SCID; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SMALL MOLECULE LIBRARIES; STEROID HYDROXYLASES; TUMOR CELLS, CULTURED; VITAMIN D;

EID: 84876005786     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4119     Document Type: Article

References (50)

1. Morris HA. Vitamin D: a hormone for all seasons-how much is enough? Clin Biochem Rev 2005;26:21-32.
2. Omdahl JL, Morris HA, May BK. Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu Rev Nutr 2002;22:139-66.
3. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007;7:684-700.
4. Vaisanen S, Dunlop TW, Sinkkonen L, Frank C, Carlberg C. Spatiotemporal activation of chromatin on the human CYP24 gene promoter in the presence of 1a,25-Dihydroxyvitamin D3. J Mol Biol 2005;350: 65-77.
5. Pike JW, Meyer MB. The vitamin D receptor: new paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D(3). Endocrinol Metab Clin North Am 2010;39:255-69, table of contents.
6. Thompson PD, Jurutka PW, Haussler CA, Whitfield GK, Haussler MR. Heterodimeric DNA binding by the vitamin D receptor and retinoid X receptors is enhanced by 1,25-dihydroxyvitamin D3 and inhibited by 9-cis-retinoic acid. Evidence for allosteric receptor interactions. J Biol Chem 1998;273:8483-91.
7. Dwivedi PP, Muscat GE, Bailey PJ, Omdahl JL, May BK. Repression of basal transcription by vitamin D receptor: evidence for interaction of unliganded vitamin D receptor with two receptor interaction domains in RIP13delta1. J Mol Endocrinol 1998;20:327-35.
8. Jurutka PW, Whitfield GK, Hsieh JC, Thompson PD, Haussler CA, Haussler MR. Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev Endocr Metab Disord 2001;2: 203-16.
9. MacDonald PN, Baudino TA, Tokumaru H, Dowd DR, Zhang C. Vitamin D receptor and nuclear receptor coactivators: crucial interactions in vitamin D-mediated transcription. Steroids 2001;66:171-6.
10. Anderson MG, Nakane M, Ruan X, Kroeger PE, Wu-Wong JR. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol 2006;57:234-40.
11. Bareis P, Bises G, Bischof MG, Cross HS, Peterlik M. 25-Hydroxyvitamin D metabolism in human colon cancer cells during tumor progression. Biochem Biophys Res Commun 2001;285:1012-7.
12. Friedrich M, Rafi L, Mitschele T, Tilgen W, Schmidt W, Reichrath J. Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res 2003;164: 239-46.
13. Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 2000;25: 144-6.
14. Mimori K, Tanaka Y, Yoshinaga K, Masuda T, Yamashita K, Okamoto M, et al. Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer. Ann Oncol 2004;15:236-41.
15. Horvath HC, Lakatos P, Kosa JP, Bacsi K, Borka K, Bises G, et al. The candidate oncogene CYP24A1: a potential biomarker for colorectal tumorigenesis. J Histochem Cytochem 2010;58:277-85.
16. Chen G, Kim SH, King AN, Zhao L, Simpson RU, Christensen PJ, et al. CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma. Clin Cancer Res 2011;17:817-26.
17. Miller GJ, Stapleton GE, Hedlund TE, Moffat KA. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1a,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1995;1:997-1003.
18. Schuster I, Egger H, Herzig G, Reddy GS, Schmid JA, Schussler M, et al. Selective inhibitors of vitamin D metabolism-new concepts and perspectives. Anticancer Res 2006;26:2653-68.
19. Yee SW, Campbell MJ, Simons C. Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells. J Steroid Biochem Mol Biol 2006;98:228-35.
20. Parise RA, Egorin MJ, Kanterewicz B, Taimi M, Petkovich M, Lew AM, et al. CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int J Cancer 2006;119:1819-28.
21. Zhang Q, Kanterewicz B, Buch S, Petkovich M, Parise R, Beumer J, et al. CYP24 inhibition preserves 1a,25-dihydroxyvitamin D(3) antiproliferative signaling in lung cancer cells. Mol Cell Endocrinol 2012;355:153-61.
22. Muindi JR, Yu WD, Ma Y, Engler KL, Kong RX, Trump DL, et al. CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology 2010;151:4301-12.
23. Luo W, Karpf AR, Deeb KK, Muindi JR, Morrison CD, Johnson CS, et al. Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. Cancer Res 2010;70:5953-62.
24. Ma Y, Yu WD, Kong RX, Trump DL, Johnson CS. Role of nongenomic activation of phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase 1/2 pathways in 1,25D3-mediated apoptosis in squamous cell carcinoma cells. Cancer Res 2006;66:8131-8.
25. Yu WD, Ma Y, Flynn G, Muindi JR, Kong RX, Trump DL, et al. Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system. Cell Cycle 2010;9:3022-9.
26. Szyszka R, Grankowski N, Felczak K, Shugar D. Halogenated benzimidazoles and benzotriazoles as selective inhibitors of protein kinases CK I and CK II from Saccharomyces cerevisiae and other sources. Biochem Biophys Res Commun 1995;208:418-24.
27. Beumer JH, Parise RA, Kanterewicz B, Petkovich M, D'Argenio DZ, Hershberger PA. A local effect of CYP24 inhibition on lung tumor xenograft exposure to 1,25-dihydroxyvitamin D(3) is revealed using a novel LC-MS/MS assay. Steroids 2012;77:477-83.
28. Kahraman M, Sinishtaj S, Dolan PM, Kensler TW, Peleg S, Saha U, et al. Potent, selective and low-calcemic inhibitors of CYP24 hydroxylase: 24-sulfoximine analogues of the hormone 1alpha,25-dihydroxyvitamin D(3). J Med Chem 2004;47:6854-63.
29. Krek W, Maridor G, Nigg EA. Casein kinase II is a predominantly nuclear enzyme. J Cell Biol 1992;116:43-55.
30. Faust M, Montenarh M. Subcellular localization of protein kinase CK2. A key to its function? Cell Tissue Res 2000;301:329-40.
31. Landesman-Bollag E, Romieu-Mourez R, Song DH, Sonenshein GE, Cardiff RD, Seldin DC. Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 2001;20:3247-57.
32. Laramas M, Pasquier D, Filhol O, Ringeisen F, Descotes JL, Cochet C. Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer. Eur J Cancer 2007;43:928-34.
33. Oc P, Rusch V, Talbot SG, Sarkaria I, Viale A, Socci N, et al. Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung. Clin Cancer Res 2004;10:5792-803.
34. Gapany M, Faust RA, Tawfic S, Davis A, Adams GL, Ahmed K. Association of elevated protein kinase CK2 activity with aggressive behavior of squamous cell carcinoma of the head and neck. Mol Med 1995;1:659-66.
35. Gotz C, Bachmann C, Montenarh M. Inhibition of protein kinase CK2 leads to a modulation of androgen receptor dependent transcription in prostate cancer cells. The Prostate 2007;67:125-34.
36. Hessenauer A, Montenarh M, Gotz C. Inhibition of CK2 activity provokes different responses in hormone-sensitive and hormone-refractory prostate cancer cells. Int J Oncol 2003;22:1263-70.
37. Khorchide M, Lechner D, Cross HS. Epigenetic regulation of vitamin D hydroxylase expression and activity in normal and malignant human prostate cells. J Steroid Biochem Mol Biol 2005;93:167-72.
38. KomagataS, Nakajima M, Takagi S, Mohri T, Taniya T, Yokoi T. Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. Mol Pharmacol 2009;76:702-9.
39. Lehen'kyi V, Raphael M, Oulidi A, Flourakis M, Khalimonchyk S, Kondratskyi A, et al. TRPV6 determines the effect of vitamin D3 on prostate cancer cell growth. PLoS One 2011;6:e16856.
40. Lehen'kyi V, Flourakis M, Skryma R, Prevarskaya N. TRPV6 channel controls prostate cancer cell proliferation via Ca(2+)/NFAT-dependent pathways. Oncogene 2007;26:7380-5.
41. Ly LH, Zhao XY, Holloway L, Feldman D. Liarozole acts synergistically with 1a,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 1999;140:2071-6.
42. Zhao XY, Ly LH, Peehl DM, Feldman D. Induction of androgen receptor by 1a,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 1999;140: 1205-12.
43. Guzey M, DeLuca HF. A group of deltanoids (vitamin D analogs) regulate cell growth and proliferation in small cell carcinoma cell lines. Res Commun Mol Pathol Pharmacol 1997;98:3-18.
44. Bremmer F, Thelen P, Pottek T, Behnes CL, Radzun HJ, Schweyer S. Expression and function of the vitamin D receptor in malignant germ cell tumour of the testis. Anticancer Res 2012;32:341-9.
45. Jiang F, Li P, Fornace AJ Jr, Nicosia SV, Bai W. G2/M arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer. J Biol Chem 2003;278:48030-40.
46. Tront JS, Hoffman B, Liebermann DA. Gadd45a suppresses Rasdriven mammary tumorigenesis by activation of c-Jun NH2-terminal kinase and p38 stress signaling resulting in apoptosis and senescence. Cancer Res 2006;66:8448-54.
47. Jurutka PW, Hsieh JC, MacDonald PN, Terpening CM, Haussler CA, Haussler MR, et al. Phosphorylation of serine 208 in the human vitamin D receptor. The predominant amino acid phosphorylated by casein kinase II, in vitro, and identification as a significant phosphorylation site in intact cells. J Biol Chem 1993;268:6791-9.
48. Jurutka PW, Terpening CM, Haussler MR. The 1,25-dihydroxy-vitamin D3 receptor is phosphorylated in response to 1,25-dihydroxy-vitamin D3 and 22-oxacalcitriol in rat osteoblasts, and by casein kinase II, in vitro. Biochemistry 1993;32:8184-92.
49. Jurutka PW, Hsieh JC, Nakajima S, Haussler CA, Whitfield GK, Haussler MR. Human vitamin D receptor phosphorylation by casein kinase II at Ser-208 potentiates transcriptional activation. Proc Natl Acad Sci U S A 1996;93:3519-24.
50. Arriagada G, Paredes R, Olate J, van Wijnen A, Lian JB, Stein GS, et al. Phosphorylation at serine 208 of the 1a,25-dihydroxy vitamin D3 receptor modulates the interaction with transcriptional coactivators. J Steroid Biochem Mol Biol 2007;103:425-9.